Neurol. praxi. 2020;21(5):400-405 | DOI: 10.36290/neu.2020.100
The most common errors in current migraine prophylaxis: case reports
- Neurologie Brno, s. r. o., a II. neurologická klinika LF a FN Brno
Prophylactic treatment is administered in order to reduce the frequency, duration, and severity of migraine attacks. The treatment is typically initiated with antiepileptic drugs or beta blockers; it is further based on the presence of other conditions, for example psychiatric ones, risks of adverse effects, and contraindications, if any. The article uses case reports to discuss the most common errors in choosing a prophylactic agent with respect to comorbidities, the timing and duration of the treatment.
Keywords: migraine, prophylaxis, topiramate, beta blockers, antidepressants.
Received: September 2, 2020; Revised: September 22, 2020; Accepted: September 23, 2020; Prepublished online: September 23, 2020; Published: November 11, 2020 Show citation
References
- Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. European Federation of Neurological Societies; EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009; 16(9): 968-981.
Go to original source... - Loder E, Birch R, Rizzoli P. The 2012 AHS/AAN Guidelines for prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Pratise Guidelines.
- Peatfield, P, Dodick, DW. Headaches. Fine Print, Oxford, 2002: 625.
- Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headaches in a general population. J Clin Epidemiol 1991; 44: 1147-1157. Go to original source...
- Silberstein SD, Holland S, Freitag F, Dodich DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78(17): 1337-1345. Go to original source...
Go to PubMed... - SÚKL. Rozhodnutí o stanovení maximální ceny a výše a podmínek úhrady ze zdravotního pojištění léčivého přípravku Aimovig. Dostupné z: www.sukl.cz (cit.31-12-2019).